Optometric Education Consultants

The ABCs of Thyroid Disease
Antibodies, Biologics, and Clinical Pearls

Greg Caldwell, OD, FAAO

Primary Eye Care Conference
Pittsburgh

Optometric Education Consultants
Saturday, February 17, 2024

2

Disclosures- Greg Caldwell, OD, FAAO
All relevant relationships have been mitigated

- Lectured for: Alcon, B&L, BioTissue, Dompé
  - Disclosure: Receive speaker honorariums
- Advisory Board: Dompé, ImmunoGen, Iveric
  - Disclosure: Receive participant honorariums
- I have no direct financial or proprietary interest in any companies, products or services mentioned in this presentation
  - Disclosure: Non-salaried financial affiliation with Pharmanex
- Healthcare Registries – Chairman of Advisory Council for Diabetes and AMD
- The content of this activity was prepared independently by me - Dr. Caldwell
- The content and format of this course is presented without commercial bias and does not claim superiority of any commercial product or service
- Optometric Education Consultants – Scottsdale, AZ, Pittsburgh, PA, Sarasota, FL , Barcelona, Spain, Orlando, FL, Mackinac Island, MI, Quebec City, Canada, and Nashville, TN- Owner

3

My Practice

I am a clinician first then a scientist
- Some are scientists first then clinician
- I need to simplify for patient and patient care.
- Science is great, but not good if there isn't a clinical application.
- Some lectures are science based without clinical application.
- My lecture will be a hybrid. Showing clinical applications of the science

It is wonderful to have someone who's juggling so many aspects of optometry [scientific, clinical experience, teacher & lecturer]. It is refreshing and very informative. -Sarah




5

"The Comfort Zone"

Confidence
Capable
Courage
Commitment

6

Key Tenants of Aging, Performance and Vitality

- Oxidative Stress / Inflammation
- Hormonal Balance
- Stress Hormones
- Glucose / Insulin Regulation
- GUT integrity and microbiome diversity
- Immune Balance
- Environmental Exposure/Burden
- Individuality

Credit to: James LaValle, RPh, CCN

7




8

9

Thyroid Disease and Thyroid Eye Disease

10

Questions

- Everyone on Synthroid is at risk for TED?
- What type of disease is TED?

11

Thyroid

- Thyroid is an endocrine gland
- Two types of glands
  - Endocrine
  - Exocrine
- Endocrine system is a control system of ductless endocrine glands that secrete hormones (chemical messenger) that circulate within the body via the bloodstream or lymph system to affect distant organs
  - Hypothalamus
  - Pituitary gland
  - Thyroid
  - Parathyroid glands
  - Pancreas
  - Adrenal glands
  - Gonads (testes and ovaries)
  - Pineal gland

12

Thyroid

- Exocrine glands contain ducts. Ducts are tubes leading from a gland to its target organ
  - Digestive glands have ducts for releasing the digestive enzymes
  - Salivary glands, sweat glands and glands within the gastrointestinal tract
- Pancreas is both endocrine and exocrine
  - Exocrine (ducted gland) secreting digestive enzymes into the small intestine.
  - Endocrine (ductless gland) in that the islets of Langerhans secrete insulin and glucagon to regulate the blood sugar level.

13

Thyroid

- Largest endocrine gland in the body
- Butterfly shaped
- Two lobes located on either side of the trachea in the lower portion of the neck
- Lies just below skin and muscle layer surface
- The thyroid is controlled by the hypothalamus and pituitary
- The primary function of the thyroid is production of the hormones thyroxine (T4), triiodothyronine (T3), and calcitonin

14

Normal Thyroid Function



15

Discussion

16

Thyroid Dysfunction

- What is the most common cause of thyroid dysfunction?
  - A. Cancer
  - B. Surgically induced
  - C. Medication toxicity or side effect
  - D. Pregnancy
  - E. Autoimmune disease
- In autoimmune disease the body typically produces _____ that attacks itself, this can be systemic or organ specific
  - Antibodies, immunoglobulins

17

Why Autoimmune Disease is on the Rise?

18

Why Autoimmune Disease is on the Rise?

"Numbers of autoimmune cases began to incre
about 40 years ago in the west," Lee told the
Observer. "However, we are now seeing some
emerge in countries that never had such diseas
before.

For example, the biggest recent increase in
inflammatory bowel disease cases has been in t
Middle East and east Asia. Before that they had
hardly seen the disease."

Autoimmune diseases range from type 1 diabet
to rheumatoid arthritis, inflammatory bowel
disease and multiple sclerosis. In each case, the
immune system gets its wires crossed and turn
on healthy tissue instead of infectious agents.

"Fast-food diets lack certain important
ingredients, such as fibre, and evidence suggests
this alteration affects a person's microbiome – the
collection of micro-organisms that we have in our
gut and which play a key role in controlling
various bodily functions," Vinuesa said.

"These changes in our microbiomes are then
triggering autoimmune diseases, of which more
than 100 types have now been discovered."

Both scientists stressed that individual
susceptibilities were involved in contracting such
illnesses, ailments that also include celiac disease
as well as lupus, which triggers inflammation and
swelling and can cause damage to various organs,
including the heart.

19

Thyroid Dysfunction

- Primary=Thyroid gland
- Secondary= Pituitary failure
- Tertiary= Hypothalamic



20

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Antibodies of Thyroid Dysfunction

- TSH Receptor Antibodies
  - Stimulating TSH receptor antibody
    - Thyroid Stimulating Immunoglobulin (TSI)
  - Thyroid blocking antibody (TBAb)
- Thyroid Peroxidase Antibodies (TPOAb)
  - TPO is found in thyroid follicle cells where it converts the thyroid hormone T4 to T3
  - TPOAb contributes to thyroid cellular destruction
- Most autoimmune thyroid dysfunctions have a combination of thyroid antibodies, however depending on which AB is more abundant results in the outcome of the disease

21



22



23

24



25



26

Hyperthyroid



- TSI attacks the thyroid
- T3 and T4 increase
- TSH decreases

27

Hypothyroid



- TBAb attacks the thyroid
- T3 and T4 decrease
- TSH increases

28

Thyroid Dysfunction

Hyperthyroidism
(Thyrotoxicosis)

- Primary-autoimmune
  - Graves
    - Graves-Basedow or von Basedow's
- Secondary/Tertiary
  - Excess thyroid medication for treatment of hypo or goiter
  - Toxic multinodular goiter
  - Toxic adenoma
  - Excess iodine
  - Thyroiditis (inflammatory induced)
  - Excess hormone production ectopic tissue
  - Thyroid carcinoma

Hypothyroidism
(most common organ-specific autoimmune disorder)

- Primary-autoimmune
  - Chronic autoimmune thyroiditis
    - Hashimoto's thyroiditis
  - Autoimmune atrophic thyroiditis
    - Primary myxedema
    - Opposite of Graves disease
  - Postpartum thyroiditis
- Secondary/Tertiary
  - Lithium medication
  - Pregnancy
  - Surgically induced
  - Disorders of the pituitary gland or hypothalamus

29

GRAVE'S
(Hyperthyoidism)

- A multisystem disorder consisting of a triad
  - Hyperthyroidism with diffuse hyperplasia of the thyroid gland
  - Infiltrative dermopathy
  - Infiltrative ophthalmopathy
- Prevalence:
  - 20-40 year old female (F:M = 7:1)
  - Genetic link
- Etiology:
  - Autoimmune disease: hypersensitivity reaction with thyroid stimulation by the circulation of abnormal thyroid-stimulating immunoglobulins (TSI)

30

Hashimoto's Thyroiditis
(Hypothyroidism)

- The most common cause of hypothyroidism in the United States
- It is named after the first doctor who described this condition, Dr. Hakaru Hashimoto, in 1912
- Autoimmune disease
- Goiter formation
- 5-10 times more common in women than in men
- The underlying cause of the autoimmune process still is unknown
  - Anti-TPO ab and Anti-TB recp ab present

31

Autoimmune atrophic thyroiditis
(Hypothyroidism)

- Atrophic thyroiditis is similar to Hashimoto's thyroiditis
- A goiter is not present

32

Postpartum Thyroiditis
(Hypothyroidism)

- These women develop antibodies to their own thyroid during pregnancy, causing an inflammation of the thyroid after delivery

33

Systemic Manifestations of Hyperthyroid
(Primary or Secondary)

- Symptoms
  - Nervousness
  - Heat intolerance
  - Sweating
  - Fatigue
  - Palpitation
  - Insomnia
  - Early waking
  - Alopecia
  - Vitiligo
  - Brittle nails
- Signs
  - Sweating
  - Muscle Weakness
  - Emotionally labile
  - Tremor
  - Tachycardia
  - Arrhythmia
  - Hypertension
  - Brisk tendon reflex
  - Diabetes
  - ↑Triglycerides & Ca, ↓CHO
  - Microcyticanemia
  - Possible goiter
  - Myxedema

34

Systemic Manifestations of Hypothyroid
(Primary or Secondary)

- Symptoms
  - Cold intolerance
  - Weakness
  - Reduced energy
  - Lethargy
  - Muscle cramps
  - Constipation
  - Increased sleeping
  - Weight gain
  - Reduced appetite
  - Joint stiffness
- Signs
  - Cool, scaling skin
  - Puffy hands and face
  - Deep voice
  - Myotonia
  - Delirium
  - Bradycardia
  - Slow reflexes
  - Obesity
  - Hypothermia
  - Myxedema

35

Thyroid Eye Disease (TED)

- Other names used
  - Grave's disease
  - Grave's ophthalmopathy
  - Grave's orbitopathy
  - Exophthalmos in Graves Disease
  - Thyroid Associated Orbitopathy (TAO)
  - Thyroid Orbitopathy
  - Ophthalmic Graves Disease
  - Inflammatory Eye Disease
  - Endocrine Orbitopathy

36

Why is this so confusing?

- Thyroid Eye Disease
  - Is often seen in conjunction with Graves' Disease (hyperthyroid)
  - Is seen in people with no other evidence of thyroid dysfunction
  - Is seen in patients who have Hashimoto's Disease (hypothyroid)
- Most thyroid patients, however, will not develop thyroid eye disease

37

Why is this so confusing?

- The eye symptoms usually occur at the same time as the thyroid disease
  - However they may precede or follow the obvious symptoms of the thyroid abnormality
- The incidence of thyroid eye disease associated with thyroid dysfunction is higher and more severe in smokers
  - There is no way to predict which thyroid patients will be affected

38

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Why is this so confusing?

- While eye disease may be brought on by thyroid dysfunction
  - Successful treatment of the thyroid gland does not guarantee that the eye disease will improve
  - No particular thyroid treatment can guarantee that the eyes will not continue to deteriorate
  - Once inflamed, the eye disease may remain active from several months to as long as three years
  - There may be a gradual or, in some cases, a complete improvement

39

Thyroid Eye Disease

- Commonly known as Graves' ophthalmopathy
- About 80% of all patients with TED have the autoimmune hyperthyroid disorder known as Graves' disease
- Another 10% of all cases are seen in patients with autoimmune hypothyroidism, either Hashimoto's thyroiditis, atrophic thyroiditis or Hashitoxicosis
- Another 10% of all cases are seen in people with normal thyroid function
  - When thyroid function is normal, the eye condition is referred to as euthyroid Graves' disease
  - Euthyroid is a term meaning that thyroid function tests are normal. Most people with euthyroid Graves' disease develop a thyroid disorder within eighteen months of the emergence of the eye disorder
  - But some people with euthyroid Graves' disease never develop thyroid dysfunction

40

Thyroid Eye Disease

- What causes the Thyroid Eye Disease signs and symptoms?
- The high and low levels of T3 and T4
- The antibodies that are attacking the thyroid gland

41

Thyroid Eye Disease

- Thyroid Eye Disease has 2 phases
  - A phase secondary to abnormal thyroid hormone levels
    - Increased or decreased FT3 and FT4 levels
    - Once these levels are normalized, ocular symptoms will resolve
  - Congestive Autoimmune form of Thyroid Eye Disease
    - Active phase-stimulating or blocking TRAb are causing ocular activity
    - Plateau phase-reduced activity
    - Resolution phase-symptoms regress and eyes return to normal

42

Phase secondary to abnormal thyroid hormone levels (T_3/T_4)
(Thyroid Eye Disease)

- Hyperthyroidism eye symptoms
  - Excess hormone acting on the nerves that supply the eye
  - Usually spastic and include staring
  - Dryness
  - Eyelid retraction
- Hypothyroidism eye symptoms
  - Deficient hormone causing venous congestion, impaired circulation and fluid stagnation
  - Periorbital edema

- This form of TED resolves within a few weeks after thyroid hormone levels (FT4 and FT3) are corrected and brought back into the normal range
- The pituitary hormone TSH can stay low or suppressed for many months during the course of treatment for hyperthyroidism and doesn't mean that the patient is still hyperthyroid
- TSH also lags at least 6 weeks behind thyroid hormone levels and often remains elevated longer in people who have been hypothyroid
- Relying on the TSH level can be misleading and in treating TED

43

Congestive Autoimmune form of Thyroid Eye Disease
(Active phase, Plateau phase, Resolution phase)

- Caused by both stimulating and blocking TSH receptor antibodies (TRAb) and also immune system chemicals known as cytokines
- Secondary targets appear to be TSH receptor antigens (epitopes) located on orbital fibroblasts as well as dermal fibroblasts
- Active "inflammatory" phase of TED varies
  - Symptoms resolve quickly although on average the active phase lasts about 12-18 months
  - TRAb levels are high, patients are smokers, nutrient deficiencies are present, or the patient continues to be exposed to environmental triggers such as excess dietary iodine, the active phase can last as long as 5 years
  - Avoid any lid, muscle or orbital surgery
- Plateau phase and Resolution "Passive" phase
  - An individual may be left with structural changes, such as eye protrusion, eyelid retraction, and in some cases, double vision
  - There are corrective procedures that can be performed to address these problems

44

Euthyroid Graves' disease

- If thyroid function is normal. How does one develop thyroid eye disease?



45

Similar receptors are found in the skin, fat and muscle of the orbit



46



You're in the Know

Normal Values
Thyroglobulin 20 IU/ml
Peroidase <35 IU/ml
TSI 1.75 IU/ml

It does work!

47

General Ocular Symptoms

- Prominent eyes, stare
- Pain
- Lacrimation
- Eyelid swelling
- Foreign-body sensation
- Double vision
- Photophobia
- Decreased vision in one or both eyes

48

NOSPECS: Grading System

- 1969 by S.C. Werner
  - **Class 0: No signs or symptoms**
  - **Class 1: Only signs, upper lid retraction**
  - **Class 2: Soft Tissue involvement with symptoms**
  - **Class 3: Proptosis**
  - **Class 4: EOM involvement**
  - **Class 5: Corneal involvement**
  - **Class 6: Sight Loss**
- Class 2-6 document severity
  - 0: absent
  - A: minimal
  - B: moderate
  - C: marked
- Within classes 2 to 6 the investigator has to differentiate the severity grades 0, A, B, C
- NOSPECS, classifies severity but not the activity or stage (active/inflammatory or passive/congestive)

49

NOSPECS: Grading System

- 0: No symptoms or signs
- 1: Only signs (upper lid retraction without lid lag or proptosis)
- 2: Soft tissue involvement with symptoms (excess lacrimation, sandy sensation, retrobulbar discomfort)
  - Grade 0: absent
  - Grade A: minimal (edema of lids, injection, sandy feeling)
  - Grade B: moderate (edema of lids, injection, chemosis, FBS, pain behind eyes)
  - Grade C: marked
- 3: Proptosis associated with classes 2-6 only
  - Grade 0: absent
  - Grade A: minimal: 21mm -23mm
  - Grade B: moderate: 24mm -27mm
  - Grade C: marked: 28mm or more
  - Specify if inequality of ≥3 mm between eyes, or if progression of ≥3 mm under observation

50

NOSPECS: Grading System

- 4: EOM involvement (usually with diplopia)
  - 0: absent
  - A: minimal (limitation of motion, patient reports diplopia but no obvious restriction
  - B: moderate (evident restriction of motion)
  - C: marked (position of globe is fixed)
- 5: Corneal involvement (due to proptosis, incomplete closure, lagophthalmos)
  - 0: absent
  - a: minimal (staining)
  - b: moderate (ulceration)
  - c: marked (clouding, necrosis, perforation)
- 6: Sight loss (due to optic nerve involvement)
  - 0: absent
  - A: minimal (disc pallor or edema, or VF defect, vision 20/20-20/60)
  - B: moderate (same as A but VA 20/70-20/200)
  - C: marked (blindness, VA < 20/200)

51

LEMO Classification

- 1991-Boergen and Pickardt
- Complements NOSPECS
- 4 finding-categories
  - Lid
  - Exophthalmos
  - Muscular
  - Optic nerve
- Grade between 0 and 4 depending on severity
- LEMO, classifies severity but not the activity or stage (active/inflammatory or passive/congestive)

52

LEMO Classification

Lid (L)
- 0: missing
- 1: lid edema only
- 2: real retraction (impaired lid closing)
- 3: retraction and upper lid edema
- 4: retraction and global lid edema

Exophthalmos (E)
- 0: missing
- 1: eye closing not impaired
- 2: conjunctival injection in the morning
- 3: persistent conjunctival injection
- 4: corneal complications

53

LEMO Classification

Muscular (M)
- 0: missing
- 1: detectable in imaging only
- 2: Pseudoparesis
- 3: Pseudoparalysis

Optic Nerve (O)
- 0: missing
- 1: regarding color vision only or detected via VEP
- 2: peripheral scotoma
- 3: central scotoma

L1E1M2O0

Endocrine ophthalmopathy with lid edema, exophthalmos , pseudoparesis of external eye muscles, and no optic nerve involvement

54

Clinical Activity Score (CAS)

- Thyroid disease characterized by:
  - Severity
  - Activity – want 3 or above
    - CAS (1-7)
- Studies for Tepezza
- Payers using CAS for approval
  - Due to wide open label
  - Those infusing are charting the CAS


Table 2 | Clinical Activity Score

	Clinical Activity Score
1	Painful feeling behind globe
2	Pain on attempted gaze
3	Redness of eyelids
4	Redness of conjunctiva
5	Chemosis
6	Inflammatory eyelid swelling
7	Inflammation of caruncle or plica
8	Increase of ≥2 mm in proptosis in last 1–3 months
9	Decrease in visual acuity in last 1–3 months
10	Decrease in eye movements of ≥8° in last 1–3 months

55

Lid Involvement

- Lid Retraction
- Lid Lag
- Lagophthalmus

56

Lid Retraction

- Scleral show in primary gaze
- Most commonly seen complication
- Occurs in ~90% of Grave's patients
  - Excess stimulation of Muller's muscle
  - Fibrotic inferior rectus
  - Mechanical restriction or infiltration of levator
  - Increased orbital volume causes exophthalmos
- Normal Lid Position
  - Upper lid intersects cornea at the 2 and 10 o' clock positions
    - ~2 mm below the limbus
  - Lower lid coincident or 1-2mm below the limbus

57

Eyelid Lag: von Graefe's Sign

- Immobility or lagging of upper eyelid on downward gaze
- Fibrosis of the inferior rectus muscle may induce lower lid retraction

58

Lagophthalmos

- Inability to form a complete lid closure with a normal blink due to Exophthalmos/ Proptosis
- Often leads to corneal exposure

59

Soft Tissue Involvement

- Conjunctiva
- Chemosis
- Periorbital edema

60

Conjunctiva

- Conjunctival and episcleral injection
  - Especially near the horizontal recti insertions
- Chemosis
  - Edema of the conjunctiva and caruncle
- Superior Limbic Keratoconjunctivitis
  - 65% correlation between SLK and systemic thyroid disease
  - Rheumatoid arthritis
  - Sjögren's syndrome

61

"If it is Red think TED"

Dr. Andy Morgenstern 12-7-2013, OMS-Contemporary Resort

62

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Periorbital Edema

- Inflammation of the subcutaneous connective tissue
- May be first sign of thyroid eye disease
- Greatest in the morning

63

Infiltrative Orbitopathy (Exophthalmos/Proptosis)

- Thyroid Eye Disease is most common cause of unilateral and bilateral exophthalmos
- The term exophthalmos is reserved for prominence of the eye secondary to thyroid disease
- May need MRI to determine or obvious exophthalmos may be present
- It is permanent in 70% of cases
- Caused by increased volume of the extra ocular muscles
  - Lymphocytic infiltration
  - Proliferation of fibroblasts
  - Edema within the interstitial tissue of the muscle

64

Infiltrative Orbitopathy (Exophthalmos/Proptosis)



65

Infiltrative Orbitopathy (Exophthalmos/Proptosis)

66

67

Exophthalmometry

- Is race dependent (Asians versus Black men is statistically significant)
- Hertel or Luedde results
- Adults
  - Average reading 17 mm
  - 95% of population have readings between 13-21mm
- General concerns
  - A difference of 2 mm or more between the eyes
  - A measurement of more than 24 mm

Race	Mean Normal Value	Upper Limits
	mm	mm
White women	15.4	20.1
White men	16.5	21.7
Black women	17.8	23.1
Black men	18.5	24.7
Asians	----	18.0

68

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Restrictive Myopathy

- Secondary to edema and fibrosis of EOM's
- Inferior Rectus (IR) muscle is most commonly involved
- Occurs in 30-50% of patients
- Diplopia may be transient but in 50% it's permanent

69

IOP in Thyroid Eye Disease

- A rise in IOP has been reported with TED
- I would have higher suspicion when you see
  - Periorbital edema
  - Exophthalmos, proptosis
  - Restrictive myopathy
- Some literature reports IOP in up gaze to be part of the diagnoses of thyroid dysfunction

70

Restrictive Myopathy

Obvious restrictive myopathy but also note the periorbital edema, and conjunctival hyperemia

71

Corneal Exposure

- Exposure keratopathy secondary to exophthalmos and lagophthalmos
- Significant threat to visual function



72

Optic Neuropathy

- Affects 5% of patients
- Usually mild to moderate exophthalmos and shallow orbits
- Enlargement of the recti muscles compresses ONH or its blood supply at the apex of the orbit
- Compression MAY occur without significant proptosis
- Compressive and/or ischemic and/or toxic

73

Treatment of Thyroid Eye Disease

- Depends on what phase of the disease we are in:
  - Phase secondary to abnormal thyroid hormone levels
  - Active "inflammatory" phase
  - Plateau phase and Resolution "Passive" phase
- Depends on what orbital tissue or structures are involved
- Depends on the risk of vision loss
- Depends if primary, secondary or tertiary thyroid dysfunction
- Management consists of:
  - Control of inflammation
  - Prevention of ocular and visual damage
  - Addressing ocular motor abnormalities
  - Improving cosmetic disfigurement
- Patient education is essential
- Communication with an endocrinologist or internist will ensure proper patient care

74

Treatment of Thyroid Eye Disease

- Palliative (hormone imbalance, active, passive)
  - Lubricants
  - Topical anti- inflammatory (Lotemax/Restasis)
  - Prisms
- Steroids (active phase)
  - Orals
  - Peri-ocular injections
  - IV with oral steroid taper
- Orbital radiotherapy (active phase)
- Orbital Decompression (passive phase)
  - Fat removal orbital decompression (FROD)
    - Large orbits
  - Bone removal orbital decompression (BROD)
    - Small orbits
  - Both FROD and BROD

Smoking causes the thyroid eye disease to be more severe
Smoking causes treatments to be less effective

75

Treatment of Thyroid Eye Disease

- Paradigm shifts
  - Decrease in orbital radiotherapy
  - Waiting for passive stage but doing surgery
  - Increase usage of fat removal orbital decompression as first approach
  - Peri-orbital injection of steroids for recurrent disease after orals
- Future
  - Looking for better or different ways to treat the active phase of this disease

76

Lid Retraction, Eyelid Lag, Lagophthalmos

- Must treat underlying thyroid dysfunction
- Abnormal hormone level and Active phase
  - Treat the exposure keratitis with lubricants
  - Tape eyelids shut at night
  - Lid weight
  - Moisture chamber at night
  - Antibiotic ointments
- Passive Phase
  - Surgical Management
  - Inferior rectus recession
  - Mullerotomy
  - Recession of lower lid retractors

77

Lid Retractor Surgery

78

Conjunctiva, Periorbital edema

- Topical lubricants
  - Artificial tears
  - Ointments at night
  - Topical steroids
  - Restasis?
- Tape eyelids closed at night or use mask
- Elevate head at night to decrease lid edema
- Oral diuretics Acetazolamide
- Oral steroids
  - 60-80mg/day for 3 months
- IV steroids
- Periorbital steroids
  - Kenalog last 1 month

79

Infiltrative Orbitopathy (Exophthalmos/Proptosis)

- Orbital Disease Consult
  - Systemic steroids to reduce inflammation
  - Low dose radiotherapy
  - Surgical orbital decompression

80

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Restrictive Myopathy

- Non-surgical (while waiting for stability)
  - Teach proper head position to alleviate diplopia
  - Prism in spectacle correction (Fresnel or ground in)
  - Oral steroids
  - Botulinum toxin injection
- Surgical Consult
  - Recession of the rectus muscle/s involved
  - Diplopia in primary gaze, reading gaze or both
  - Stable angle of deviation for at least 6 months
  - No evidence of active disease
  - Binocular vision in at least primary and reading positions

81

Corneal Exposure

- Manage the corneal defect as first line
  - Lubricating and antibiotic
  - Lid taping
  - Moisture barrier
- Orbital Disease Consult
  - High dose oral steroids
    - 120-140mg /day x 7 days
  - Orbital decompression



82

Optic Neuropathy

- Systemic Steroids
  - If rapidly progressive and painful in the early stage of the disease
  - Only if no contraindications
  - Prednisolone 80-100mg, expect results within 48hrs. Taper dose and d/c within 3 mo
- IV Methylprednisolone
- Radiotherapy: if contraindication to steroid
- Orbital decompression

83

Orbital Decompression

- Not effective if no medical treatment
  - Two-wall decompression
    - 3-6 mm retro-placement of the globe
  - Three-wall decompression
    - 6-10mm retro-placement
  - Four-wall decompression
    - 10-16mm retro-placement



84

Orbital Decompression
(Surgical/Cosmetic)

85

Thyroid Eye Disease and Depression

- When facial disfigurement occurs, thyroid eye disease is equivalent to the diagnosis of cancer and AIDS

86

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Orbital Decompression
(Medical/Vision Threatened)

87

IOP in Thyroid Eye Disease

- A rise in IOP has been reported with TED
- I would have higher suspicion when you see
  - Periorbital edema
  - Exophthalmos, proptosis
  - Restrictive myopathy
- Some literature reports IOP in up gaze to be part of the diagnoses of thyroid dysfunction….let's discuss

88

IOP in Thyroid Eye Disease

89

Laboratory Testing

- Thyroid Hormone Levels
  - Serum TSH concentration Serum total T4 (Thyroxine)
  - Serum total T3 (Triiodithyronine)
  - Estimation of the serum free T4 (or T3) concentration
  - Thyroglobulin (Tg) level
- Anti-thyroid antibodies
  - Thyrotropin receptor antibodies (TSI)
  - TSH binding inhibiting immunoglobulins (TBII)
  - Anti-TPO antibodies
  - Thyroglobulin (Tg) Antibodies (TgAb)
- Commonly used thyroid tests
  - Resin T3 uptake test
  - Sensitive serum TSH test (Thyroid stimulating hormone)
  - TRH stimulation test (Thyroid releasing hormone)
  - Thyroid (T3) suppression test
  - Sonography
  - Needle Biopsy
  - Thyroid Scan

90

Laboratory Testing

- Hypothyroid
  - Low FT4, High TSH, indicates primary check antibodies
  - Low FT4, Low TSH, indicates secondary or tertiary, TRH stimulation, MRI
  - Hashimoto's (primary disease)
    - Most common
    - Low FT4, High TSH, High Anti-TPO Ab, High levels of Thyroglobulin (Tg) Antibodies (TgAb), Anti-TB Recp Ab (approx 10% present)
  - Autoimmune atrophic thyroiditis
    - Low FT4, High TSH, Low Anti-TPO Ab, Low levels of Thyroglobulin (Tg) Antibodies (TgAb), Anti-TB Recp Ab (approx 60% present)
  - Treatment: Levothyroxine (*Synthroid, Levothroid, Levoxyl, Unithroid)*
- Hyperthyroid
  - High FT4, Low TSH
  - TSI present

91

February 25, 2019
"Nothing Else Can Be Done"

92

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell



93

94

95

96

97

98

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

99



100

101

102



103

104

105

Teprotumumab-trbw (Tepezza)

- Horizon Therapeutics – HQ Dublin, Ireland and US based Chicago
- Biologic pharmaceutical
  - Chinese Hamster Ovary
  - Infusion, 8 total, every 3 weeks
- Thyroid eye disease
  - IGR-1 (Insulin like growth factor 1) and TSH receptors are over expressed
- IGF-1 receptor inhibitor monoclonal antibody
  - On the orbital fibroblasts
    - Inhibiting downstream inflammatory cascade
      - Cytokines, hyaluran, leukotriene
      - Differentiation into adipocytes and myofibroblasts
- Phase 2 and published in New England Journal of Medicine
- Phase 3 completed
  - Published - New England Journal of Medicine
- PDUFA- March 2020, was approved early in 2020

106

Teprotumumab-trbw (Tepezza)



107

Immunosuppression?

- Biologics
  - Immunosuppression biologics – suppress the immune system to get the effe3ct
    - Remicade – "1st generation"
      - Chimeric molecule – mouse and human protein, a lot of sensitivity
    - Humira
      - Anti-TNF (RA and Crohn's Disease
      - Fully human protein, less sensitivity
    - Rituxan
      - CD 20 suppressor (B cell suppression)
    - Actively suppress the immune system
  - Immunomodulary
    - Tepezza
      - IGF-1R inhibitor
      - Full humanized monoclonal antibody
        - All the proteins are human – less to no sensitivity – more focused effect
      - Obital fibroblasts to myofibroblast or adipocytes
      - Hyaluronic acid, glycosaminoglycan

108

Teprotumumab-trbw (Tepezza)

- Optics and Optic-X Studies
  - 8 infusions, every 3 weeks, 24 weeks
  - Optics – acute, less than 9 months of disease
  - Optics X – chronic, 12-16 months disease
- Clinical Activity Score
  - Spontaneous pain, gaze evoked pain, eyelid erythema, chemosis, inflammation
  - Scale of 7, needed 4 to be in the study
- Proptosis
  - Improvement of 2 mm or better
- Diplopia
  - Scale of 0, 1, 2, or 3
- Grave's Ophthalmopathy -Quality of Life Score
  - Scale 0-100

109

Teprotumumab-trbw (Tepezza)

- Clinical Activity Score (CAS)
  - Spontaneous pain, gaze evoked pain, eyelid erythema, chemosis, inflammation
  - Scale of 7, needed 4 to be in the study
    - 78% improved to 0 or 1, 7% improved 0 or 1 with placebo
- Proptosis
  - Improvement of 2 mm or better
    - 83% had 2 mm or better, 10% with placebo
    - Average was 3.2 mm at week 24
- Diplopia
  - Scale of 0, 1, 2, or 3
    - 68% improved 1 point, 29% with placebo
- Grave's Ophthalmopathy -Quality of Life Score
  - Scale 0-100
    - 17.28 point improved, 1.80 with placebo

110

Teprotumumab-trbw (Tepezza)

- **Adverse Reactions**
  - **Very well tolerated**
  - The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

111

Teprotumumab-trbw (Tepezza)

- **Infusion Reactions (mild/moderate):** approximately 4% of patients
  - transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain
  - consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering at a slower infusion rate.
- **Hyperglycemia:** Increased blood glucose or hyperglycemia
  - In clinical trials, 10% of patients experienced hyperglycemia
  - Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with teprotumumab
  - Patients with preexisting diabetes should be euglycemic before beginning treatment

112

Teprotumumab-trbw (Tepezza)

- Infusion center
  - Go to Horizon website
  - Contact Us
  - Type in your question
    - Looking for infusion center

113

Biologics Used Off Label for TED



114

Optometry's Opportunity

115

Eyelash and Brow Loss

- Hypothyroidism or hyperthyroidism, hair loss can be an unfortunate side effect
- Dry, brittle hair, thinning on the scalp, and even loss of lashes and brows
- Some drugs used to treat thyroid conditions can also contribute to the loss of hair
- Left untreated, the hormonal changes associated with hypothyroidism or hyperthyroidism can completely stop new hair strands from developing

116

Greg A Caldwell, OD, FAAO
Greg@optometricedu.com 814-931-2030 cell

Current Treatments

- Latisse – bimatoprost 0.03%
- Lash Boost – Rodan Fields - contain isopropyl cloprostenate
  - Synthetic analog of the medication found in Latisse.
  - Highly potent prostaglandin F2-alpha receptor agonist



117

New and All Natural

- Lash and Brow Serum – Nu Colour – Nu Skin
  - June 22, 2023 – Available in USA
  - Formulation of natural extracts and peptides
  - Prostaglandin free
  - BAK free
  - No Rx needed – sold in the office
  - Clinical studies preformed

118

Lash and Brow Serum

- No Prostaglandin analogs
  - 3 peptides and 5 extracts
- No iris or skin color changes
- No BAK
  - No impact to dry eye
- Not a prescription
- Safe for contact lens wears
- Works within 4 weeks
- 1 bottle (5 ml) lasts 2-3 months
- 3-year self life
- Favorable pricing and profitability
- Able to offer a safer solution to the patient
- Able to capture a part of this $1.7 billion USD market
- Resources for your office – posters and banners

119

New and All Natural

120

Functional Interventions

Immune System Support
Gut Microbiome Support

121



122

123



124



125



126

127



128

129



130



131

132



133



134



135



136



137



138



139

140


Signs in Thyroid Eye Disease
Dalrymple's sign: Lid retraction
von Graefe's sign: Upper lid lag on downward gaze
Griffith's sign: Lower lid lag on downward gaze
Boston's sign: Jerky irregular movement of the upper lid on downward gaze
Jellinek's sign: Increased pigmentation of the lids
Stellwag's sign: Infrequent blinking
Kocher's sign: Increased lid retraction with visual fixation
Enroth's sign: Puffy swelling of the lids
Rosenbach's sign: Tremor of closed lids
Mobius' sign: Weakness of convergence
Ballet's sign: Palsy of one or more extraocular muscles
Suker's sign: Weakness of fixation on lateral gaze
Cowen's sign: Jerky papillary contraction to consensual light
Knies' sign: Unequal dilatation of the pupils
Jeffrey's sign: Absence of forehead wrinkling on upward gaze

141


Optometric Education Consultants
Questions and Thank You!
The ABCs of Thyroid Disease
Antibodies, Biologics, and Clinical Pearls
Greg Caldwell, OD, FAAO
Primary Eye Care Conference
Pittsburgh
Optometric Education Consultants
Saturday, February 17, 2024

142